Anlotinib reverses osimertinib resistance via inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer.

IF 2.2 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL
Liting Lv, Xin Hua, Jiaxin Liu, Sutong Zhan, Qianqian Zhang, Xiao Liang, Jian Feng, Yong Song
{"title":"Anlotinib reverses osimertinib resistance <i>via</i> inhibiting epithelial-to-mesenchymal transition and angiogenesis in non-small cell lung cancer.","authors":"Liting Lv, Xin Hua, Jiaxin Liu, Sutong Zhan, Qianqian Zhang, Xiao Liang, Jian Feng, Yong Song","doi":"10.7555/JBR.38.20240045","DOIUrl":null,"url":null,"abstract":"<p><p>In the present, we aimed to investigate the effect of anlotinib on the potential reversal of osimertinib resistance by inhibiting the formation of epithelial-to-mesenchymal transition (EMT) and angiogenesis. In a clinical case, anlotinib reversed osimertinib resistance in Non-small cell lung cancer (NSCLC). We performed an immunohistochemical experiment on tumor tissues from three non-small cell lung cancer patients exhibiting osimertinib resistance to analyze alterations in the expression levels of EMT markers and vascular endothelial growth factor A (VEGFA) before and after osimertinib resistance. The results revealed the downregulation of E-cadherin, coupled with the upregulation of vimentin and VEGFA in tumor tissues of patients exhibiting osimertinib resistance, compared with the expression in tissues of patients before taking osimertinib. Subsequently, we established osimertinib-resistant cell lines and found that the osimertinib-resistant cells acquired the EMT features. Then, we analyzed the synergistic effects of the combination therapy to verify whether anlotinib could reverse osimertinib resistance by inhibiting EMT. The expression levels of VEGFA and micro-vessels were analyzed in the combination group <i>in vitro</i>. Finally, we explored the reversal of osimertinib resistance in combination with anlotinib <i>in vivo</i> with 20 nude mice. The combined treatment of osimertinib and anlotinib effectively prevented the metastasis of resistant cells, which also inhibited tumor growth, exerted anti-tumor activity, and ultimately reversed osimertinib resistance in mice. The co-administration of osimertinib and anlotinib demonstrated their synergistic efficacy in inhibiting EMT and angiogenesis in three NSCLC patients, ultimately reversing osimertinib resistance.</p>","PeriodicalId":15061,"journal":{"name":"Journal of Biomedical Research","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biomedical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7555/JBR.38.20240045","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

In the present, we aimed to investigate the effect of anlotinib on the potential reversal of osimertinib resistance by inhibiting the formation of epithelial-to-mesenchymal transition (EMT) and angiogenesis. In a clinical case, anlotinib reversed osimertinib resistance in Non-small cell lung cancer (NSCLC). We performed an immunohistochemical experiment on tumor tissues from three non-small cell lung cancer patients exhibiting osimertinib resistance to analyze alterations in the expression levels of EMT markers and vascular endothelial growth factor A (VEGFA) before and after osimertinib resistance. The results revealed the downregulation of E-cadherin, coupled with the upregulation of vimentin and VEGFA in tumor tissues of patients exhibiting osimertinib resistance, compared with the expression in tissues of patients before taking osimertinib. Subsequently, we established osimertinib-resistant cell lines and found that the osimertinib-resistant cells acquired the EMT features. Then, we analyzed the synergistic effects of the combination therapy to verify whether anlotinib could reverse osimertinib resistance by inhibiting EMT. The expression levels of VEGFA and micro-vessels were analyzed in the combination group in vitro. Finally, we explored the reversal of osimertinib resistance in combination with anlotinib in vivo with 20 nude mice. The combined treatment of osimertinib and anlotinib effectively prevented the metastasis of resistant cells, which also inhibited tumor growth, exerted anti-tumor activity, and ultimately reversed osimertinib resistance in mice. The co-administration of osimertinib and anlotinib demonstrated their synergistic efficacy in inhibiting EMT and angiogenesis in three NSCLC patients, ultimately reversing osimertinib resistance.

安罗替尼通过抑制上皮细胞向间质转化和血管生成逆转非小细胞肺癌对奥希替尼的耐药性
本研究旨在探讨安罗替尼通过抑制上皮细胞向间质转化(EMT)的形成和血管生成,对可能逆转奥希替尼耐药性的影响。在一个临床病例中,安罗替尼逆转了非小细胞肺癌(NSCLC)的奥西莫替尼耐药性。我们对三例奥希替尼耐药的非小细胞肺癌患者的肿瘤组织进行了免疫组化实验,分析了奥希替尼耐药前后EMT标志物和血管内皮生长因子A(VEGFA)表达水平的变化。结果显示,与服用奥希替尼前相比,奥希替尼耐药患者肿瘤组织中E-cadherin下调,波形蛋白和VEGFA上调。随后,我们建立了奥希替尼耐药细胞系,发现奥希替尼耐药细胞具有EMT特征。随后,我们分析了联合治疗的协同作用,以验证安罗替尼是否能通过抑制EMT逆转奥希替尼耐药。我们在体外分析了联合治疗组中 VEGFA 和微血管的表达水平。最后,我们以20只裸鼠为研究对象,探讨了奥希替尼联合安罗替尼在体内逆转奥希替尼耐药性的情况。奥希替尼与安罗替尼联合治疗可有效阻止耐药细胞的转移,同时抑制肿瘤生长,发挥抗肿瘤活性,最终逆转小鼠对奥希替尼的耐药性。奥西美替尼和安罗替尼联合用药在三例NSCLC患者中显示出抑制EMT和血管生成的协同疗效,最终逆转了奥西美替尼耐药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biomedical Research
Journal of Biomedical Research MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
4.60
自引率
0.00%
发文量
69
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信